An interventional study of InSpace Subacromial Tissue Spacer in Rotator Cuff Tears, sponsored by Stryker Endoscopy. Recruiting at 11 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-29.
Sponsored by Stryker Endoscopy (part of Stryker) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Rotator Cuff Injuries by Stryker — 2 open to participants now, 3 under way, none of them phase 3. Rotator Cuff Injuries · Stryker.
Among the 12 studies in Rotator Cuff Injuries by Stryker, this one is the only one that started in 2022, is one of 9 with no phase, and was the 10th registered.
632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.
Browse Rotator Cuff Injuries studies →2 of the 12 studies in Rotator Cuff Injuries by Stryker are open now, in 1 country. Recruiting first, the newest first:
Stryker Trauma and Extremities · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 160 is above the median of 60 across 456 interventional studies indexed under Rotator Cuff Injuries.
Median enrollment 45 across the 9 interventional studies, 110 across the 3 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Stryker Endoscopy, one of the names counted as Stryker. Under that name alone:
Stryker Endoscopy is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Rotator Cuff Injuries by Stryker, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, parallel group, open-label, multi- center, randomized study to assess two accelerated rehabilitation programs for use with the InSpace device in the treatment of full thickness Massive, Irreparable Rotator Cuff Tears (MIRCTs) performed during an arthroscopic procedure.
Study Objectives:
Primary:
Secondary:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects MUST meet ALL the following criteria to be included in the study:
Positive diagnostic imaging by MRI within 9 months of enrollment of the index shoulder indicating a full thickness MRCT:
Failed non-operative treatment of at least 3 months from the initial treatment to include one or more of the following:
Intra-operative Inclusion Criteria
Subjects MUST meet the following criteria to be randomized in the study:
Exclusion Criteria:
Subjects will be excluded from the study, if they meet ANY of the following individual exclusion criteria:
Evidence of the following conditions:
The subject requires concomitant:
Intra-operative Exclusion Criteria:
Subjects will not be randomized and will be terminated from the study if they meet ANY of the following individual intra-operative exclusion criteria:
Rotator cuff is/presents with:
The subject requires concomitant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
InSpace device + accelerated rehabilitation in a formalized program (FP)
Device: InSpace Subacromial Tissue Spacer
InSpace device + accelerated rehabilitation in an at-home program (AHP)
Device: InSpace Subacromial Tissue Spacer
Rotator Cuff Tear Treatment
Change in American Shoulder and Elbow (ASES) Score
This is a subject self-report questionnaire and Investigator assessment questionnaire. The subject portion collects information on activities of daily living (i.e., 10 questions). The Investigator assessment portion documents ROM (forward elevation/flexion, external rotation, internal rotation, cross-body adduction), signs, strength, and instability. ASES minimal clinical important difference (MCID) and substantial clinical benefit (SCB) have been previously described for the ASES score in patients undergoing rotator cuff repair as 11.1 and 17.5, respectively. Change in American Shoulder and Elbow Surgeons (ASES) Score will be expressed as the percentages demonstrating a minimal clinical important difference (MCID; ASES ≥ 11.1) and the substantial clinical benefit (SCB; ASES ≥ 17.5) in ASES from baseline at Month 12. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome).
Time frame: Day 0 through Month 12
Safety Assessment
• Safety will be evaluated by type, frequency, severity, and relatedness of adverse events to study intervention at each follow-up visit through Month 24
Time frame: Day 0 through Month 24
Change in Western Ontario Rotator Cuff (WORC) Score
Change in WORC Score from baseline. Minimum value: 2,100, Maximum value: 0 (with a lower score indicating a better outcome). This is a subject self-report questionnaire that is a disease-specific Quality of Life Measurement Tool specifically designed to evaluate quality of life in persons with pathology of the rotator cuff. It is comprised of 21 items in 5 domains (i.e., physical symptoms, sports and recreation, work, lifestyle, emotions).
Time frame: Day 0 through Month 24
Change in Constant Score (CS) Outcome Score
Change in CS Outcome Score from baseline. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome). This is a self-reported questions as well as Investigator or designee performed assessment of the shoulder. The tool is divided into four subscales: pain, activities of daily living, strength and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder.
Time frame: Day 0 through Month 24
Change in EuroQol 5-Dimensions Questionnaire (EQ-5D-5L) Score
Change in EQ-5D-5L Score from baseline. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome). This is a subject self-report questionnaire to measure health-related quality of life (HRQOL). It consists of 5 questions capturing the subject's current health across five dimensions (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). It also includes a numerical visual analogue scale (EQ-VAS).
Time frame: Day 0 through Month 24
Change in Visual Analog Scale (VAS) Score
Change in VAS Score from baseline. This is a subject self-report questionnaire to measure pain. The patient marks on the line the point that they feel represents their perception of their current state. The amount of pain that a patient feels ranges across a continuum from none to an extreme amount of pain. (An extreme amount of pain would be considered a worse outcome)
Time frame: Day 0 through Month 24
Change in Range of Motion (ROM) Score
Change in ROM Score from baseline. Minimum value: 0, Maximum value: 180 (with a higher score indicating a better outcome).
Time frame: Day 0 through Month 24
Change in Single Assessment Numeric Evaluation (SANE) Score
Change in SANE from baseline. Minimum value: 0%, Maximum value: 100% (with 100% being normal). This is a subject self-report questionnaire to measure function. The patient marks on the line the point that they feel represents their perception of their current state of functional improvement. Example: "How would you rate your affected shoulder today as a percentage of normal (0% to 100% scale with 100% being normal)?"
Time frame: Day 0 through Month 24
Patient's satisfaction with their procedure
Patient Satisfaction Score at Month 12 and Month 24. This is a single-question to evaluate the patients' current state of satisfaction. Responses are binary with Yes or No answers. ('Yes' would be considered a positive outcome)
Time frame: Month 12 and Month 24
Costing
Costs associated with all visits
Time frame: Day 0 through Month 24
Time to Recovery
Time to recovery by cumulative time between discharge and return to driving
Time frame: Day 0 through Month 24
Analgesia Use
Analgesia use (drug and frequency)
Time frame: Day 0 through Month 24
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Apr 2026, 50 months after the start.
Of 252 interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.